SAN FRANCISCO, June 17, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Singular Bio, ...
SAN FRANCISCO, Jan. 22, 2024 /PRNewswire/ -- Invitae (NVTA) (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which ...
Invitae Corp. wants a piece of the prenatal screening pie, and the company just struck two deals to make that happen. Invitae Corp. wants to be a comprehensive provider of genetic information through ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical ...
Just a few weeks after earning a permanent injunction barring the use of Invitae’s Personalized Cancer Monitoring tests, Natera is taking another of the diagnostic developer’s product portfolios off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback